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rNTRODUCTION
During the past decade, 2 major cytolytic path-
ays used by natural killer (NK) and T cells have been
horoughly described. Both the perforin/granzyme
nd death receptor (ie, fas/fas ligand [fasL]) pathways
ltimately result in apoptosis of the targeted popula-
ion [1]. Studies have been preformed using mutant
nd knockout strains to investigate NK and T-cell
mpairment in viral and tumor immune responses, as
ell as in transplantation models, to investigate the
ontribution of these pathways in resistance to alloge-
eic cell engraftment [2-9]. Several early studies
ielded interesting results with regard to cytolytic de-
ciencies and so-called allograft resistance. For exam-
le, major histocompatibility complex (MHC)–het-
rozygous recipients were observed to reject donor
arental marrow despite granzyme B deﬁciency [4].
dditionally, lethally conditioned MHC-disparate re-
ipients deﬁcient in perforin or expressing defective
asL were also able to reject allogeneic hematopoietic
rafts after a standard dose of bone marrow (BM) was
ransplanted [2].
By using a different approach in which diphtheria
oxin was transgenically expressed under a granzyme B
romoter to broadly eliminate cytolytic barrier cell
opulations, results were obtained that were similar to
hose described previously: no detection was reported
f diminution in NK resistance to hematopoietic stem t
B&MTell (HSC) grafts [10]. In contrast, adoptively trans-
erred peripheral blood mononuclear cells from syn-
eneic donors treated with isoleucyl methyl ester
which lyses cytotoxic granule-containing cells [11])
ailed to reject most dog leukocyte antigen–mis-
atched BM grafts [12]. Such studies were followed
y investigations that examined how the simultaneous
eﬁcit of cytolytic molecules affected resistance me-
iated by T and NK cells [6-9,13]. Although initially
erhaps surprising to many investigators, the results of
hese studies have consistently demonstrated that re-
istance in most models remains relatively intact de-
pite the absence of perforin or fasL and, in some
ransplant conditions, efﬁcient when multiple cyto-
ytic pathways are lacking [2,4-6,9,10] (see below).
uch ﬁndings—that the host can apparently summon
variety of potent effector pathways to thwart suc-
essful engraftment of progenitor cell allografts and
oped-for tolerance after transplantation—are not
nly biologically intriguing, but also important from
he clinical perspective. This review discusses ﬁndings
btained from several transplantation models investi-
ating how resistance to stem/progenitor cells is me-
iated, particularly with respect to the involvement of
ytolytic pathways used by NK cells and effector cells
erived from naive and memory T-cell populations in
ecipients conditioned for allogeneic HSC grafts. On
he basis of published ﬁndings to date, we hypothe-
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9ized that transplantation conditions determine the
elative importance of host cytotoxic pathways in re-
isting allogeneic hematopoietic cell engraftment.
HE “BARRIER”
A major obstacle toward more universally success-
ul allogeneic hematopoietic stem/progenitor cell
ransplantation (HSPCT) is circumvention of the im-
une-mediated resistance present in the recipient
14]. This so-called barrier is composed of multiple
ell types, including NK and T-cell populations (Ta-
le 1) [15-20]. Moreover, depending on the recipient’s
tate of antigen exposure, effector cells may be gen-
rated from a host T-cell compartment composed of
oth naive T-cell and memory T-cell populations.
ne report noted anti-HLA class I antibody in a
atient who rejected an allogeneic BM graft, and a
ecent study observed that preformed antibody against
HC-disparate grafts can contribute to rejection,
resumably as a result of anti-MHC antibody binding
o cell-surface donor antigens [21] (P. Taylor and B.
lazar, University of Minnesota, unpublished data).
lthough antibodies against minor histocompatibility
ntigen (MiHA) peptides have been identiﬁed in
SPCT recipients [22,23], there have been no re-
orts of antibody-mediated resistance against MHC-
atched hematopoietic grafts. Notably, increased lev-
ls of bcl-2 in CD8 memory T cells selectively favor
heir survival versus naive T cells after total body
rradiation [24]. Overall, despite considerable insult to
he host immune system resulting from chemother-
py, radiation treatment, or both (ie, antitumor ther-
py/conditioning before HSPCT), all of these cell
opulations can persist and mediate immune re-
able 1. Cell Populations That Can Effect Resistance in Experimental
Variable
aive host (unprimed to donor alloantigen)
MHC mismatched
Host  Donor MHC
A ¡ A/B None
A ¡ B Full
A ¡ B Class I only
A ¡ B Class II only
MHC matched
A.2 ¡ A.1 None
ensitized host (primed to donor alloantigen)
MHC mismatched
A ¡ B Full
MHC matched
A.2 ¡ A.1 None
This population is responsible for early (days 1-5) resistance.
This population contributes after 5 to 6 days after transplantation
Italic signiﬁes the effector population predominantly responsible
Z.Z., A.S., and R.B.L., unpublished data.
Anti-donor MHC antibody may contribute to resistance in MHC cB. Blazar, unpublished data).
58ponses, thus preventing successful long-term hema-
opoietic engraftment by transplanted donor stem/
rogenitor cells [25,26]. The continued development
nd implementation of reduced-intensity conditioning
rotocols to diminish regimen-related toxicity and
omplications of immune deﬁciency (ie, infection) un-
erscores the need to inhibit/regulate host resistance
27,28]. Moreover, recently it has been found that
linically, the loss of donor chimerism in these non-
yeloablative settings can be associated with higher
ates of relapse [27].
Experimental models of allograft resistance, prin-
ipally in the mouse, have led to a greater understand-
ng of the cellular players that mediate resistance in
ifferent transplantation settings (Table 1). However,
he cells within the heterogeneous hematopoietic
tem/progenitor cell (HSPC) population that are tar-
eted for rejection and, importantly, the ultimate fate
or such cells continue to be unclear. Regarding the
ormer, resistance activity against short-term repopu-
ating and committed progenitor cells may or may not
e identical to activity against long-term HSCs, in
art as a consequence of potentially different repopu-
ation locations and kinetics of these progenitors [29-
2]. Concerning the fate of targeted cells, donor
SPC target populations recognized by host NK
nd/or T-cell effector cells could undergo apoptosis.
lternatively, the resistance phenotype would also be
anifest if HSPCs were functionally inhibited but
ersistent in the recipient, unable to proliferate or
ndergo differentiation (Figure 1). Moreover, the mo-
ecular mechanisms by which the host immune system
ffects rejection of donor progenitors remains to be
ully elucidated. It is interesting to note that the trans-
lantation setting itself must be considered because
of Hematopoietic/Stem and Progenitor Cell Transplantation
NK* Naive T Cell† Memory T Cell References
ition
Yes‡ No No 18, 33
Yes Yes No 17, 19, 20
Yes Yes No 34
No Yes No 34, 35
No Yes No 105§
Yes Yes Yes 9, 26, 72
No Yes Yes 6, 9, 13, 73
stance under the conditions of transplantation listed.
–mismatched recipients sensitized to donor antigens (P. Taylor andModels
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Cytolytic Pathways in Allogeneic Hematopoietic Cell Transplantation
Besistance in naive versus antigen-sensitized recipients
r after nonablative versus ablative conditioning could
nderstandably lead to different effector pathways
Table 1; Figure 1). Recent ﬁndings from our own
aboratory and others support the notion that effector
echanisms used by NK and primed T-cell popula-
ions may be nonoverlapping or possibly distinct (see
elow) [6,8,9,13]. Therefore, identifying the precise
olecular pathways responsible for progenitor allo-
raft resistance remains a primary challenge for im-
unologists as a prelude to developing approaches
hat selectively diminish a patient’s antigraft response
hile preserving his or her overall immune function,
ncluding antitumor responses early after transplanta-
ion.
FFECTOR CELLS AND
RANSPLANTATION CONDITIONS
Several cellular constituents that contribute to the
llograft resistance barrier have been well character-
zed in experimental models in the mouse (Table 1).
he acute rejection of allogeneic marrow can occur
ithin several days of transplantation in irradiated
igure 1. Summary of parameters that affect the outcome of en-
raftment after allogeneic hematopoietic cell transplantation. Fac-
ors such as the nature of pretransplantation conditioning, prior
ensitization to donor alloantigen, and the genetic disparity between
he donor and the recipient can affect the cellular constituency of
he host immune barrier to alloengraftment. This barrier could be
ediated by the induction of apoptosis or other effector pathways.
b indicates antibody; PC, progenitor cell.
able 2. Methods for Analyzing the Presence of Transplanted Cell Popu
Method Advan
pleen cell proliferation assay Early assessment
himerism in central/peripheral
compartment
Can determine multiple hem
multiple compartments; crogenitor cell assay Very early assessment; can determ
B&MTecipients [33]. Several elegant studies [15-20] dem-
nstrated that acute rejection in unsensitized mice can
nvolve NK cells, NKT, CD8 T cells, and other
opulations. Findings by Vallera and colleagues [34]
howed that CD4 and CD8 T cells can reject T
ell–depleted marrow. These studies demonstrated
hat T-cell subsets can act independently of each other
n this process because marrow from C57BL/6 con-
enic mice differing at a single MHC class I (bm1) or
lass II (bm12) locus was capable of being rejected by
ost CD4 or CD8 cells, respectively. Sprent and
olleagues [35] further demonstrated that transfer of
D4 T cells into class II–disparate recipients re-
ulted in marrow destruction, and the authors pro-
osed that this hematopoietic attack was dependent on
lass II recognition of progenitor cells because an
HC class II/ inoculum was not eliminated. We
ave recently observed that rejection of T cell–de-
leted BM transplanted from MHC-matched/MiHA-
ismatched donors occurs in nonablatively condi-
ioned CD8/ recipients; this supports the notion
hat the host CD4 subset can contribute to the re-
ection of marrow cells (Z.Z. and R.B.L., unpublished
ata). We have also examined resistance in MiHA-
isparate recipients primed to donor alloantigens
6,9]. Anti-CD8 antibody treatment of such hosts
bolishes resistance, thus indicating that a population
f CD8CD4 T-memory (CD44Ly6Chi; A.S. and
.B.L., unpublished data) cells was responsible for
esistance in these recipients [13] (Table 1).
An important characteristic of the resistance pro-
ess against progenitor cell allografts is that there is a
inetic difference between the actions by host NK and
-cell populations. Three approaches for assessing
he presence of donor transplanted cells are generally
sed in resistance studies (Table 2). These methods
ave different strengths and limitations but together
ave enabled insights into the kinetics and other as-
ects of the rejection process. In murine models using
odeoxyuridine uptake, NK cells were shown to effect
ejection early (within 48 hours) after transplantation
33,36]. Recent studies in our laboratory directly as-
essing transplanted donor progenitor populations as
n indicator of resistance have identiﬁed functional
ransplanted progenitor cells in host compartments as
arly as 2 hours after transplantation [37]. Donor
after Progenitor Cell Allografts
Limitations
Cannot discriminate between different
cell lineages and does not enable
long-term assessment
ietic lineages in
ess long term
Cannot enable early assessmentlations
tages
atopo
an assine specific lineages Cannot assess mature cell populations
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9rogenitor cells were virtually undetectable at 24 to 48
ours after transplantation in lethally conditioned
HC-mismatched allogeneic recipients unsensitized
o donor antigens, whereas signiﬁcant donor colony-
orming unit/interleukin (IL)–3 and colony-forming
nit/high proliferative potential populations were
learly present at these times in NK-depleted (anti-
K1.1 monoclonal antibody [mAb]) mice (A.S. and
.B.L, unpublished data). In contrast to NK effects, the
inetics of T cell–mediated resistance are clearly distinct.
n recipients not sensitized to donor antigens, resistance
annot be demonstrated for approximately 5 to 7 days
fter transplantation in MHC-mismatched models after
ransplantation of overriding BM cell doses (too many
ells for the NK compartment to eliminate) into MHC-
ismatched recipients [19,38]. Our recent observations
egarding resistance in unsensitized MHC-matched/
iHA-mismatched recipients—in which NK cells are
ot contributory—reﬂect similar kinetics, because di-
inishing levels of peripheral chimerism could not be
etected before 5 to 7 days after transplantation (Z.Z.
nd R.B.L., unpublished data). In contrast, resistance in
HC-matched mice sensitized to donor allogeneic an-
igens can be detected within 2 days [13].
The identiﬁcation of NK and T cells in the resis-
ance process led to questions regarding how these
opulations mediate barrier activity. Are cytolytic
athways induced by these cells required for effective
esistance (Figure 2)? As noted previously, transgenic
ice defective in NK- and T cell–mediated cytotoxic
esponses continued to resist allogeneic HSCs [10].
ur own studies have demonstrated strong resistance
o BM cell allografts in mice deﬁcient in perforin- and
asL-dependent killing if recipients possess T cells
reviously primed to donor alloantigens [6,7], whereas
thers found resistance in unsensitized recipients in-
act in the singular absence of perforin, fasL, gran-
yme B, and other cytotoxic pathways (see below)
2,4,6-9,39]. These ﬁndings raise the question: how
ritical is cytotoxicity effected by NK and T-cell pop-
lations in resistance to allogeneic HSPC?
igure 2. Lytic pathways that could contribute to resistance against
llogeneic hematopoietic stem/progenitor cells. The primary cell-
ediated lytic pathways (ie, perforin/granzyme and fasL-fas), as
ell as recently discovered death ligand/receptor pairs that could beixpressed by effector and progenitor cells.
60K CELL–MEDIATED RESISTANCE TO ALLOGENEIC
EMATOPOIETIC PROGENITOR CELL GRAFTS
Contrary to the classic rules of T cell–mediated
ejection, Cudkowicz and Bennett [40] were the ﬁrst
o demonstrate that F(1) mice were capable of reject-
ng marrow derived from a parental donor strain de-
pite the absence of an MHC alloantigen disparity.
he cells primarily responsible for this so-called hy-
rid, as well as allogeneic MHC resistance, were later
dentiﬁed as NK cells [15,18,41] and thoroughly re-
iewed [42]. NK cell alloreactivity occurs in part as the
esult of the absence (“missing self”) of signaling by
ransmembrane NK-inhibitory receptors, which re-
uire engagement of self-MHC, thereby permitting
K-activating receptors to signal induction of effec-
or pathways [43,44]. Subsequent to these seminal
tudies, transplantations involving MHC-mismatched
ecipients never exposed to donor alloantigen demon-
trated that the initial participants in this acute resis-
ance process are also NK cells [19].
Despite the importance of NK cells in marrow
llograft resistance, the target population(s) of the NK
ell within the HSPC inoculum is currently unknown.
ome experiments suggest that the HSC itself may
ot be susceptible to lysis by the NK cell. For exam-
le, puriﬁed HSCs cocultured before transplantation
ith recipient NK cells from MHC-disparate animals
howed no differences in their capacity to rescue le-
hally irradiated syngeneic recipients [31]. It is possi-
le that the signals necessary to make the HSCs sus-
eptible to NK-mediated attack are absent in vitro;
lternatively, we hypothesize that more committed
rogenitor cell populations may be the targets of NK-
ediated lysis in vivo [32]. HSCs could be capable of
voiding recognition by NK cell populations, for ex-
mple, by expressing a paucity of activation-inducing
igands [45]. It is interesting to note that stem cell
opulations in general may not be readily lysed by NK
ells. Despite their inability to induce inhibitory
y49-mediated signaling because of low or no MHC
lass I expression [46,47], studies in our laboratory
ave recently shown that neural stem cells were also
ot lysed by syngeneic or allogeneic NK cells, regard-
ess of the absence or presence (after cytokine induc-
ion) of self-MHC class I molecules [48]. Perhaps the
ntigens required for NK recognition by activating
eceptors are not present on these progenitor popula-
ions. Recent studies reported that other stem cell
opulations, ie, embryonic stem cells, also do not
eem susceptible to NK effector cell–mediated lysis
49]. It is interesting to consider that stem cells may
nherently posses the ability to evade or diminish host
mmune responses. Several studies have reported the
bility of stem cell populations, including mesenchy-
al stem cells and HSCs, to inhibit or downregulatemmune responses in vitro and in vivo [50,51]. Nota-
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Cytolytic Pathways in Allogeneic Hematopoietic Cell Transplantation
Bly, mesenchymal stem cell populations have recently
een reported to posses the capacity to inhibit both
aive and memory antigen–speciﬁc T cells [51].
Although NK cell involvement in acute graft re-
ection is well established in mice, evidence for NK-
ediated rejection in clinical transplant recipients is
ifﬁcult to establish. Clinical ﬁndings have been re-
orted that indicate that certain HLA-C determinants
orrelate with an increased risk of graft rejection.
LA-C is most often recognized by killer inhibitory
eceptors (KIRs) on human NK cells [52]; therefore,
missing” HLA-C determinants on donor cells would
ikely result in a strong host anti-donor NK reactivity.
urrently, there is no adequate method to conclu-
ively discriminate NK from T-cell involvement in
linical graft failure. In the context of progenitor cell
ransplantations, alloreactive human NK populations
ave been recently proposed to mediate antilympho-
ematopoietic tumor effects after HSPCT [53]. This
nterpretation was based on clinical ﬁndings in which
reater graft-versus-leukemia activity after allogeneic
one marrow transplantation (BMT) reportedly was
ssociated with donor/recipient pairs in instances in
hich the recipient lacked ligands for KIR on donor
ells. In contrast, a recent study by another group
ailed to observe such a correlation between graft-
ersus-leukemia and KIR mismatch in a small series of
onmyeloablative clinical transplantations [54]. Re-
ardless, although it seems that NK populations could
lso be important in mediating allogeneic graft versus
ost under appropriate genetic conditions, clinical
ndings to support this pathway remain elusive.
HE INVOLVEMENT OF CYTOTOXIC PATHWAYS
N NK-MEDIATED RESISTANCE TO PROGENITOR
ELL GRAFTS
Several studies in murine models have investigated
otential mediators of NK-dependent marrow allo-
raft rejection [4,7,8,10]. Such responses could be
ediated via cytotoxic pathways, the elaboration of
ytokines that affect hematopoiesis, or some presently
nknown mechanism. To effect target cell lysis, NK
ells have been shown to depend on either the per-
orin/granzyme exocytosis pathway or the tumor ne-
rosis factor (TNF) family of death-inducing ligands
55-60]. The most well characterized death ligand is
asL (CD95L), which is expressed by both NK and
ctivated T cells [1,56,58]. Upon ligation with their
oncomitant ligand, TNF receptor (TNFR) family
eath receptors can effect several cellular programs,
ncluding apoptosis—a process dependent on recruit-
ent and activation of procaspase 8 (see review [61]).
lternatively, or in addition to cytolytic molecules,
ctivated NK cells can elaborate multiple cytokines,
ncluding interferon-, transforming growth factor-, f
B&MTL-12, and TNF-. With respect to progenitor cell
ngraftment, each of the cytokines noted has been
hown to affect progenitor cell function and hemato-
oiesis [62-68]. Because cytokines such as transform-
ng growth factor- can mediate both stimulatory and
nhibitory activity on different progenitor populations
nd because individual cytokine effects can be altered
n the presence of other cytokines, it is difﬁcult to
nderstand how an individual cytokine could be glo-
ally responsible for allograft rejection.
Several studies have examined the involvement of
he 2 major cytotoxic effector pathways used by NK
ells, ie, perforin/granzyme and fasL, in HSPC rejec-
ion [2,4,5,7,8]. Initial studies from this laboratory
sing B6 (H2b) perforin/ mice that underwent
ransplantation with MHC-disparate marrow from
ALB/c (H2d) donors showed, to our surprise, that
apid, ie, NK-dependent, resistance occurred in these
ecipients [2]. These ﬁndings clearly indicated that
nder the conditions of those transplantations (lethal
otal body irradiation and complete MHC-mismatched
M), perforin-deﬁcient NK cells seemed to be fully
apable of resisting a standard dose (2  106) of
ransplanted allogeneic BM. Granzyme B, although
equired for rapid perforin-dependent lysis of target
ells in vitro, also was not required for HSPC rejec-
ion in vivo because granzyme B/ recipients were
apable of rejecting BM grafts as efﬁciently as wild-
ype mice in a hybrid resistance model [4]. Additional
tudies in perforin-deﬁcient mice found that although
erforin was not required for NK-mediated rejection,
he NK cell compartment could be overridden by
ransplantation of fewer HSPCs in perforin-deﬁcient
ice compared with perforin-competent recipients
8]. Such observations support a role for perforin/
ranzymes for optimal NK-dependent resistance. Ge-
etic differences between mouse strains and environ-
ental conditions in animal housing facilities were
lso found to inﬂuence the perforin dependence of
K-mediated HSPC rejection. B6.129 perforin/
ice exhibited a deﬁciency in NK-mediated rejection
nly after transfer from a speciﬁc pathogen–free en-
ironment to a conventional housing facility [5]. In
hese experiments, rejection in the absence of perforin
lso proceeded even in the presence of blocking mAb
o interferon- and IL-12: this suggests that these 2
olecules may also not be required in this rejection
rocess. In total, the ﬁndings to date indicate that
hereas perforin is an important molecule that NK
ells use in resistance, distinct cytotoxic or noncyto-
oxic pathways can clearly effect rejection if the per-
orin/granzyme pathway is absent. A question remain-
ng is the relative contribution of such pathways when
erforin is present in the resisting host NK popula-
ions. Regardless, it is important to consider that in-
ervention strategies targeting the inhibition of per-
orin-mediated pathways in host NK cells may not
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9revent resistance, depending on the conditions of the
ransplantation.
In addition to the perforin/granzyme effector path-
ay, the involvement of death receptor pathways has
lso been studied in murine models of NK-mediated
esistance. Baker et al. [2] found that transplantation
f 2  106 BM cells into lethally irradiated recipients
xpressing nonfunctional fasL were capable of reject-
ng MHC-mismatched BM allografts, thereby dem-
nstrating that this ligand was not required for this
K-mediated resistance. To prevent possible com-
ensation by a perforin pathway in this model (and by
asL in the perforin-deﬁcient recipients noted previ-
usly), lpr (fas-deﬁcient) donor marrow was infused
nto perforin/ mice, thus creating a double-deﬁ-
ient transplant. Transplantation of MHC-disparate
arrow from C3H.HeJ lpr (H2k) donors was also
esisted in perforin/ recipients [2]. Thus, even
hough resistance by H2b recipients against H2k do-
ors is genetically “weak” [33], NK-mediated rejec-
ion of the “standard” (2  106) marrow dose seemed
o occur in the absence of the 2 major cytotoxic path-
ays, with the caveat that the lpr mutation is “leaky”;
herefore, some fas expression could not be ruled out
n marrow cells [69]. Nonetheless, these ﬁndings led
s to hypothesize that alternative pathways, distinct
rom the perforin/granzyme and fasL/fas pathways,
re likely to exist in recipients after transplantation
hat can effect resistance to progenitor allografts.
An eloquent approach to examine the involvement
f death receptors other than fas used a strategy in
hich HSPCs were transduced with a retroviral vector
hat expressed the caspase 8 inhibitor cFLIP [7].
ransplantation of these class I–deﬁcient progenitor
opulations into perforin/ recipients resulted in di-
inished resistance in this NK-dependent model.
ne interpretation of this ﬁnding was that some
aspase 8–dependent extrinsic apoptotic signal may
ediate an additional pathway by which NK cells can
ffect allograft resistance [7]. It is interesting to note
hat blockade of the caspase 8–dependent pathways in
his study did not confer complete protection from
K-mediated rejection: this suggests that a third
echanism distinct from perforin or TNF family
eath receptors may be contributory. Furthermore,
tudies in which B6.129 or B6 perforin/ mice un-
erwent transplantation with B6-lpr transporter-asso-
iated protein (TAP)-deﬁcient marrow (thus resulting
n NK-dependent resistance) found that resistance
as weaker in the concomitant absence of perforin-
nd fasL-mediated lytic pathways, particularly in the
6.129 recipients [5]. These ﬁndings again demon-
trate a role for perforin- and fasL-dependent effector
athways in NK-mediated resistance. It is interesting
o note that neutralizing anti-TNF mAb administered
o B6.129 or B6 perforin/ recipients did not further
nhibit this NK-dependent resistance [5,8]. In sum- r
62ary, the ﬁndings published to date have observed
hat in the absence of individual cytolytic pathways,
ome or almost no dimunition of resistance against
M allografts is observed in NK-dependent models
2,4,5,7-10,39]. However, concomitant absence of the
ajor cytolytic pathways signiﬁcantly reduces NK-
ependent resistance.
CELL–MEDIATED RESISTANCE TO ALLOGENEIC
EMATOPOIETIC PROGENITOR CELL GRAFTS
The NK compartment represents the initial im-
unologic barrier that a donor HSPC must circum-
ent after transplantation of MHC-mismatched mu-
ine BM if engraftment is to take place. However,
resumably in part because of the numbers of NK
ells and limited expansion of the compartment, this
arrier can be overridden by increasing the number of
ransplanted cells [19]. Subsequently, surviving host
nti-donor reactive T cells provide a second and
tronger immune barrier to successful engraftment
hat, however, can also be overridden with large (ie,
ega) doses of progenitor cell–containing inoculum
70,71]. As noted previously, T-cell involvement, in-
luding both CD4 and CD8 subsets, is well estab-
ished in murine and canine models of allograft resis-
ance (Z.Z. and R.B.L., unpublished data)
9,19,34,35,72,73]. Although there is a paucity of in-
ormation regarding NK-mediated resistance in hu-
ans, several studies have implicated host T cells in
linical cases of graft failure [27,74-77]. In both HLA-
atched and -mismatched allogeneic recipients, host
D8 and CD4 T cells capable of anti-donor cyto-
ytic activity have been isolated from the peripheral
lood of patients undergoing acute allograft rejection
74,76-78]. Additionally, early recovery of the host
D8 compartment positively correlates with an in-
reased risk of graft rejection, and it has recently been
uggested that residual host cytotoxic T lymphocytes
CTLs) and IL-2–producing CD4 T-helper cells are
esponsible for the unstable mixed chimerism ob-
erved after nonmyeloablative conditioning and trans-
lantation [27].
Not surprisingly, individuals unintentionally sen-
itized (eg, aplastic anemia patients) or experimental
nimal recipients intentionally sensitized to donor an-
igens possess even stronger barriers to successful al-
ogeneic engraftment compared with recipients who
re naive with respect to donor antigens [6,9,79-87].
s noted previously, in murine models involving
HC-matched/MiHA-mismatched (ie, T cell–medi-
ted) transplantations, recipients possessing primed
ost T-cell populations (ie, memory T cells) have
een shown to resist hematopoietic allogeneic grafts
ith enhanced kinetics compared with unsensitized
ecipients [6,9,13,38]. In contrast to the NK barrier, it
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Cytolytic Pathways in Allogeneic Hematopoietic Cell Transplantation
Bs extremely difﬁcult to override resistance in mice
ossessing anti-donor memory T-cell populations.
tudies in our laboratory have found that megadosing
he HSPC inoculum, ie, transplanting up to 3  107
onor MiHA-mismatched marrow cells, continues to
e efﬁciently rejected by 5 days after transplantation
n recipients previously sensitized against donor anti-
ens [9].
The graft rejection that occurs in patients with
evere aplastic anemia who have received HSPCT
rom HLA-identical sibling donors is most likely the
esult of prior transfusion-induced sensitization to do-
or MiHA [85,88,89]. Such responses likely involve
ost anti-donor T-cell populations, including T mem-
ry cell effector pathways. With respect to such “sen-
itized” recipients (Figure 1), recent ﬁndings regard-
ng the unexpected presence of antigen-speciﬁc T
ells in mothers many years after childbirth may be
mportant to consider regarding resistance to engraft-
ent after clinical HSPCT in such individuals (Figure
). It is well established that pregnancy can lead to
llogeneic immunization and development of antibod-
es against paternal HLA and erythrocytes, as well as
ther antigens [90,91]. It is interesting to note that
irect evidence has recently been reported involving
omen who have never received transplants or trans-
usions indicating the presence of antigen-speciﬁc T
ells directed against paternal transplantation antigens
92,93]. After parturition, exposure to paternally de-
ived alloantigens can apparently sensitize maternal T
ells to MiHAs [93-96]. A recent study identiﬁed cir-
ulating T cells in 5 (all female) out of 17 donors with
-cell receptors speciﬁc for H-Y–encoded antigens
92]. Another investigation examined peripheral blood
rom healthy multiparous females and, by using
LA-A2 tetramer reagents, identiﬁed HA-1–, HA-2–,
igure 3. Potential barrier composition in women after allogeneic
SPCT. Depending on the genetic disparity between donor and
ecipient and the potential presence of anti-donor reactive T mem-
ry cells, the cellular constituency of the immune-mediated barrier
o alloengraftment may be composed of multiple cell populations in
he recipient. For example, sensitization to paternally derived al-
oantigens during pregnancy is one setting in which anti-donorclloantigen-reactive memory T cells could be generated.
B&MTnd H-Y–speciﬁc T cells in 4 of 7 donors up to 22
ears after their last delivery [97]. Although presently
nknown, perhaps the risk factor of graft-versus-host
isease associated with female to male and female to
emale transplantations involves responses by trans-
erred alloreactive donor memory T cells after alloge-
eic clinical BMT [98].
In contrast to experimental animals typically
oused in relatively pathogen-free environments, in-
ividuals are continually exposed to multiple environ-
ental and pathogenic antigens throughout their life-
imes. Because many such antigen encounters will
esult in memory cell generation, a reasonable hy-
othesis regarding the resultant memory T-cell pop-
lations is that some cells may possess an alloreactive
-cell receptor [99]. This phenomenon, termed het-
rologous immunity, was reportedly responsible for
eightened rejection of cardiac allografts observed in
ecipients 1 month after lymphocytic choriomenin-
itis virus infection [99]. The generation of T cells
ith cross-reactivity against HLA antigens has been
emonstrated for HLA-B8–restricted Epstein-Barr
irus–speciﬁc T-cell clones and is consistent with ob-
ervations in mice reporting the generation of allo-
eactive T cells after exposure to murine cytomegalo-
irus and other viruses [99-102]. This group of
ndings suggests that memory T cells speciﬁc for
lloantigen may clinically be considerably more fre-
uent than previously appreciated. If this is true, it is
onceivable and even likely that a signiﬁcant number
f clinical transplantations may involve a host memory
-cell component that might inﬂuence the strength of
esistance after an allogeneic HSPCT. Because mem-
ry cells are more difﬁcult to tolerize than naive T-cell
opulations, regulation of such cells to circumvent a
ost’s barrier toward the establishment of HSPC en-
raftment would be a challenging task during the post-
ransplantation period [103].
HE INVOLVEMENT OF CYTOTOXIC PATHWAYS IN
CELL–MEDIATED RESISTANCE TO PROGENITOR
ELL GRAFTS
Similar to NK cell barrier activity, the precise
olecular pathway(s) by which T-cell populations
ediate resistance to allogeneic HSPC is also not
lear. The ﬁndings to date concerning the use of
ytotoxic pathways by host T cells are particularly
ntriguing. Our own experimental studies have inves-
igated whether CTLs are a prerequisite for effective
esistance against allogeneic MiHA-mismatched pro-
enitor cells [6,9,13]. As noted previously, studies have
solated and cloned anti-donor alloreactive CTLs
rom primates as well as mice rejecting hematopoietic
rafts [26,104]. Subsequently, several murine CTL
lones were found to be capable of transferring resis-
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9ance to nonresistant recipients [104], and several clinical
tudies have identiﬁed the presence of host anti-donor
D8 clones [76,78] in patients who experienced graft
ailure. Some of these clones were able to lyse donor-
erived targets in vitro. However, the presence of
nti-donor CTLs in recipients after transplantation or
he fact that transferred CTLs can mediate resistance
oes not constitute mea culpa in the transplantation
etting or conclusively demonstrate that CTLs are
equired for the resistance process. In fact, accumu-
ating evidence from studies in murine models contin-
es to demonstrate that efﬁcient T (as well as NK)
ell–mediated resistance against allogeneic progenitor
ell grafts can occur in the absence of the major
omponents of cellular cytotoxic pathways [2-10].
Several experimental models have been designed
o speciﬁcally study resistance principally—if not ex-
lusively—mediated by host T cells (Table 1). One
pproach examines the resistance that occurs after
ransplantations between MHC-identical/MiHA-dis-
arate donor/recipient pairings [6,9,105]. Because NK
ells contribute a signiﬁcant barrier against MHC-
isparate transplantations, MHC-matched/MiHA-
ismatched transplantation models effectively enable
solated study of T cells in the rejection process. Other
pproaches speciﬁcally deplete the host NK compart-
ent by administering antibodies directed against the
K1.1 or DX5 molecules before transplantation,
hereas other models take advantage of the fact that
nly the T-cell compartment can be speciﬁcally and
arkedly expanded in response to alloantigen expo-
able 3. Cytotoxic Effector Pathways Examined in Resistance against A
Resistance Model Cytotoxic Defi
ost unsensitized to donor antigens
Hematopoietic
histoincompatibility (parent
into F1 transplant) Granzyme B
MHC class I* Perforin
Perforin
Perforin  CD95
Death receptors
MHC class I/II Perforin
CD95L
MHC matched Perforin
CD95L
Perforin and fasL
ost sensitized to donor antigens
MHC class I/II Perforin  CD95L  TNF
MHC matched Perforin
CD95L
Granzyme B
Perforin  CD95L  TNF
Perforin  CD95L  TRA
TWEAK
Resistance in these studies was mediated by host NK cells because
origin) marrow.
Studies using puriﬁed allogeneic HSCs.64ure (ie, priming) [19]. Resistance in such sensitized
iHA-disparate recipients therefore should reﬂect
he nature of a primed, ie, memory, response in that
arge numbers of donor cells should be rejected with
apid kinetics [9,13,38].
Experimental ﬁndings from our laboratory trans-
lanting BM from MHC-matched donors into recip-
ent mice sensitized to donor MiHA and singly or
oubly deﬁcient in the major mediators of cytotoxicity
ave demonstrated that T cell–dependent HSPCT
ejection is virtually unimpaired and proceeds in a
emarkably rapid and efﬁcient manner [6,9]. The host
arrier in MiHA-disparate recipients sensitized to donor
lloantigens requires a radioresistant CD8 T cell–
ependent pathway [9,13]. Mice either individually or
imultaneously lacking perforin or fasL did not dem-
nstrate any defects in the ability to reject MHC-
atched/MiHA-disparate or MHC-disparate grafts
Table 3) [2] as determined by both kinetics of rejec-
ion (both B6 wild type and B6 cytotoxic double-
efective [cdd] mice reject within 48 hours of BMT),
ven after transplantation of high numbers of BM cells
6]. In total, these studies eliminated the possibility of
ompensation between granule exocytosis–dependent
nd fas-dependent cytolytic contributions effecting
ejection and indicate that (1) an efﬁcient resistance
athway is mediated in the absence of concomitant
erforin and fasL and (2) if differing effector pathways
re used in cytotoxically normal and deﬁcient mice,
he barrier response seems to arise in the same time
eriod after transplantation.
c HSPCT
Barrier Activity in Host
Cells
Involved References
Intact NK 4
Intact (clean environment) 5
Partial loss (conventional) 5
Partial loss 8
Partial loss 7
Intact NK  T 2, 39†
Intact 2, 39†
Intact T Table 4
Intact Table 4
Diminished Table 4
TRAIL Intact T 9
Intact T 6
Intact
Intact 9
TRAIL Intact 9
L1a 
Intact T 13
bsence of MHC class I on syngeneic donor (ie, TAP/ or 2u/llogenei
cit
R1 
R1 
IL  T
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Cytolytic Pathways in Allogeneic Hematopoietic Cell Transplantation
BThe participation of other death ligand receptor
ignaling pathways by host T cells has also been ex-
mined [9,13]. B6 cdd mice have been challenged with
M from TNFR1- or TNFR2-deﬁcient donors. TNF
an initiate an apoptotic program either through the
eath domain containing TNFR1 or through TNFR2
9,106] to effectively create cytotoxic triple-defective
ransplants. It is interesting to note that no impair-
ent in resistance has been observed in these trans-
lants. Examination of TNF involvement in NK-me-
iated marrow graft resistance by using anti-TNF
Ab infusion also failed to identify a contribution by
his lytic pathway in these models [5].
Recently, several additional TNF family apop-
osis-inducing receptors/ligands have been identi-
ed, including DR3/TL1a, TWEAK/Fn14,
RAIL/DR4, LT/LIGHT, and DR6, that also
ould be proposed to play a role in the resistance
rocess [61,107-112]. To study the involvement of
everal of these molecules in resistance dependent
n T cells, B6 cdd mice sensitized against donor
lloantigens underwent transplantation with the ad-
inistration of high levels of blocking mAbs to
isrupt the signaling dependent on 3 ligand-recep-
or pairs (Table 3). These experiments consistently
ound that B6 cdd T cells again mediated efﬁcient
esistance with the disruption of TRAIL-,
WEAK-, DR3-, fasL-, and perforin-mediated cy-
otoxicity, even when all 5 pathways were concomi-
antly disrupted [13]. Taken together, the data from this
roup of studies support the notion that in antigen-
ensitized individuals, in whom resistance is principally
ependent on responses by effector cells derived from
he host memory T-cell pool, known cytotoxic pathways
o not seem to be required to mediate rejection against
SPC populations. However, one cannot formally ex-
lude the contribution of a presently uncharacterized
eath receptor pathway capable of mediating strong re-
istance. Moreover, although apoptosis can proceed
hrough the extrinsic pathways discussed previously that
nvolve signaling through death receptors, programmed
able 4. Resistance after Mini-BMT in Unsensitized Recipients Occurs
asL-Dependent Cytotoxicity
Recipient (5.5 Gy) Marrow Donor*
1. B6-wt C3H.SW
2. B6-perf/ C3H.SW
3. B6-gld/ C3H.SW
4. B6-cdd C3H.SW
5. B6-perf/ (B6  C3H)F1
6. B6-perf/ (B6  C3H)F1-lpr‡
t indicates wild type; perf, perforin; cdd, cytotoxic double deﬁcie
A total of 4  106 MHC-matched, MiHA-mismatched C3H.SW a
were transplanted.
Donor chimerism was assessed at weekly intervals by analysis of pe
The lpr mutation results in very low levels of fas messenger RNA and al
B&MTell death can also occur via an intrinsic or mitochondri-
l-dependent pathway initiated by diverse events such as
rowth factor deprivation or DNA damage (Figure 1).
herefore, if the target HSPC population does undergo
poptosis during resistance, it may not be due entirely or
t all to an extrinsic, death receptor–dependent pathway.
t present, the involvement of the intrinsic apoptotic
athway in HSPC rejection has not been examined and
hould therefore not be excluded.
Recent studies in our laboratory have been examin-
ng T cell–mediated resistance after MiHA-mismatched
MT in nonmyeloablatively conditioned cytotoxically
mpaired recipients who have not been sensitized to
onor antigens (Z.Z. and R.B.L., unpublished data). Re-
istance was evident in recipients lacking perforin
MiHA-mismatched donors, Table 4, line 2; MHC-mis-
atched donors, Table 4, line 5) and recipients lacking
unctional fasL (Table 4, line 3) that was indistinguish-
ble from that in cytotoxically unimpaired (B6 wild-type)
ecipients (Table 4). These ﬁndings could indicate that
ither pathway is sufﬁcient to effect resistance in such
ecipients. A recent study also found that transplantation
f puriﬁed allogeneic stem cells into recipients with de-
ects in individual cytotoxic pathways did not result in
ltered resistance [39]. Recent ﬁndings in our laboratory
ndicate that combined deﬁciency in both perforin and
asL diminishes resistance in recipients of MHC- or
iHA-mismatched transplants (Table 4, lines 4 and 6).
uch results suggest that, similar to the ﬁndings in NK-
ependent models, these observations support a require-
ent for cytotoxic function for optimal resistance by
ffector cells arising from naive host T cells in unsensi-
ized recipients.
UMMARY AND FUTURE DIRECTIONS
Host immunologic resistance against allogeneic
SPCT is of clinical concern, particularly in cases
nvolving an HLA disparity and T cell–depleted pro-
enitor cell inoculum [113]. The increasing trend to
Individual but Not Combined Absence of Host Perforin- and
Lytic Pathway(s) Not
Used by the Host
Donor Chimerism (>1%)
3 wk after BMT†
None 0/11
Perforin 0/9
fasL 0/14
Perforin  fasL 11/14
Perforin 0/3
Perforin  fasL 3/3
, generalized lymphoproliferative disorder.
107 MHC-mismatched (B6  C3H)F1 BM cells (T-cell depleted)
l blood staining for Ly9.1 (C3H.SW) or H2Kk (C3H) expression.in the
nt; gld
nd 1 
riphera
most undetectable levels of cell-surface fas expression [118].
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9ncorporate less ablative conditioning regimens will
ontinue to demand the understanding and regulation
f recipient anti-MHC and MiHA-speciﬁc allogeneic
mmune responses after transplantation [27]. During
he past 3 decades, experimental studies have identi-
ed important cellular effector populations of resis-
ance operative in a variety of allogeneic transplanta-
ion settings, including donor/recipient pairs who are
HC mismatched and MHC matched and in the
ontext of prior sensitization to donor alloantigens
Figure 1; Table 1). T and NK cells are clearly im-
ortant host elements after MHC-disparate transplan-
ations, whereas T cells are important in situations in
hich there is a MiHA disparity only or in recipients
n whom prior sensitization to donor antigens has
ccurred. Because these same cell populations are crit-
cal for immune defense against infectious agents and
alignancies after transplantation, it is extremely im-
ortant to identify the effector mechanisms in HSPC
esistance to enable selective inhibition of rejection while
inimally affecting their host defense capability.
In HLA-disparate HSPCTs and transplantations
n which there has been no prior sensitization to
onor alloantigens, experimental studies suggest that
K cells can contribute to acute resistance. The role
f cytotoxicity in NK-mediated rejection and the lytic
athways used by these cells is complex. Although the
erforin/granzyme exocytosis pathway is required for
n vitro NK cytotoxicity, it was not found to be re-
uired for all NK-mediated rejection events in exper-
ments that used MHC-disparate as well as TAP/
SPCT grafts [2,4,5]. However, in some experimen-
al settings, perforin-deﬁcient recipients exhibit a di-
inished ability to effect NK-mediated resistance
5,7,8]. Some of the nonperforin cytolytic effector
ctivity by NK cells seems to result from the use of
aspase 8–mediated extrinsic apoptotic pathways, al-
hough the speciﬁc ligand/receptor interactions re-
ain to be elucidated [56,59]. Intriguingly, with the
isruption of both perforin- and caspase 8–dependent
athways, NK cells continue to retain some capacity
o reject allogeneic HSPCT [7]. Elaboration of this
ffector pathway may lead to insights on how to limit
K-mediated rejection of HSPC while maintaining
elective NK cell functions against viral pathogens or
alignancies in recipients.
In addition to the barrier effected by NK cells, T
ells also contribute resistance after MHC-mismatched
SPCT. In recipients of transplants that have been
LA matched and in individuals who have received
rior exposure by natural or iatrogenic means to do-
or alloantigen, recipient T cells are the major im-
une barrier to successful donor engraftment. Al-
hough the presence of anti-donor CTL activity
orrelates with resistance in patients, the requirement
or this functional population within both CD8 and
D4 subsets for rejection has not been formally dem- a
66nstrated. In several experimental models, the transfer
f in vitro–derived CTL populations into nonresis-
ant recipients was shown to confer resistance [104]
M.K. and R.B.L., unpublished data). It is interesting
o note that the singular absence of perforin or fasL
oes not abrogate the ability to reject MHC-matched
iHA-mismatched marrow (Table 4) or MHC-mis-
atched stem cells in nonablatively and ablatively
onditioned recipients, respectively [39]. This does
ot eliminate a role for cytotoxicity in these responses,
ut it is consistent with the possibility that more than
single effector pathway may be invoked by the host
o resist engraftment. Models speciﬁcally examining
esistance between MHC-matched MiHA-mis-
atched donor/recipient combinations in which the
ecipient has been sensitized to donor alloantigens
ave repeatedly found that the combined absence of
erforin and fasL, together with TNFR1 or 2 ab-
ence—or together with the inhibition of additional
eath ligand/death receptor (TRAIL-DR5, TL1a-
R3, and TWEAK-Fn14) signaling pathways—does
ot abrogate and seems not to dampen effective graft
esistance [6,9,13].
Thus, despite extensive investigation of cytotoxic-
ty in experimental immune-mediated graft resistance,
he studies to date cannot rule out the presence and
ontribution of noncytotoxic mechanisms. As noted
reviously, allogeneic HSCs can be rejected compe-
ently in unsensitized mice that express a diphtheria
oxin transgene regulated by the granzyme A pro-
oter [10]. Theoretically, this model results in elim-
nation of CTLs and NK cells. One interpretation of
his ﬁnding is that non-CTL populations of effector
cells may participate in resistance; this is consistent
ith the notion that cytotoxic mechanisms are not
equired in the barrier against allogeneic progenitor
ell engraftment. However, our recent studies in non-
yeloablated recipients of MiHA-mismatched BM
emonstrate that perforin- or fasL-mediated function
s, in fact, required for the allograft resistance ob-
erved. In contrast, several studies involving recipients
ensitized against donor alloantigens support the pos-
ibility that T cell–mediated resistance against
SPCT grafts may be effected through noncytotoxic
athways [6,9,13]. Whether such pathways are com-
ensatory in the absence of cytotoxic mediators or are
f primary importance is presently unclear. Regard-
ess, these observations are important to appreciate in
he design of strategies to support progenitor cell
ngraftment and inhibit immune-mediated resistance.
f, in fact, under any transplantation conditions, cyto-
oxic pathways are not used by the host, what is the
verall fate of the HSPC in such a rejection process?
o these progenitor populations undergo apoptosis or
lternatively persist in the host, perhaps functionally
nhibited in their capacity to proliferate or differenti-
te (Figure 1)? For example, CD70 (found on acti-
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Cytolytic Pathways in Allogeneic Hematopoietic Cell Transplantation
Bated T cells) signaling via CD27 can inhibit myeloid
ifferentiation and long-term repopulation in vivo
114,115]. Additionally, cytokine and growth factor
ignaling can regulate progenitor cell proliferation
nd lineage commitment [116,117].
To account for the experimental ﬁndings reported
o date regarding the cell populations that mediate
esistance and the role of cytotoxicity by these cells in
he barrier to hematopoietic engraftment, a model
ust include the results pertaining to resistance by
K and T cells in both sensitized and unsensitized
rogenitor cell transplant recipients. The hypothesis
e have proposed is that the effector pathways used by
he various host populations mediating resistance dif-
er and are, therefore, at most only partially overlap-
ing (Figure 4). We interpret the ﬁndings to indicate
hat the importance of cytotoxicity in resistance path-
ays against progenitor cell allografts differs accord-
ng to the source of the host effector populations
esponsible for the barrier response, as well as the
ensitization (ie, against donor antigens) status of the
ecipient. We speculate that host effector cells derived
rom NK or naive T cells, ie, effector cells, which arise
n recipients who are not sensitized to donor graft
ntigens, require some cytotoxic-dependent pathway
eg, perforin/granzymes) to mediate strong and highly
fﬁcient resistance (Figure 4, left). In contrast, effector
ells derived from host memory T-cell populations,
e, effector cells generated in recipients previously
rimed to donor antigens, do not require known cy-
otoxic molecules to effect highly efﬁcient resistance
Figure 4, right). It is interesting to speculate that such
n immunologic pathway would not likely be limited
igure 4. A proposed model for the involvement of cytotoxic
ffector pathways in immune-mediated resistance to allogeneic he-
atopoietic stem/progenitor cell engraftment. The model presents
he hypothesis that depending on the source of the effector cells that
re generated in recipients after transplantation, the contribution of
ytotoxic pathways will differ. For example, if effector cells are
erived from naive host CD8 T cells (or NK cells), cytolytic
ctivity via perforin- or fasL-dependent pathways is critical for
eneration of a strong barrier to engraftment. In contrast, effector
ells derived from host CD8 memory T cells mediate potent
arrier activity independently of these 2 pathways.
B&MTo resistance against allogeneic hematopoietic cells
nd thus may have signiﬁcantly broader importance.
ne consequence of this hypothesis is that the suc-
essful targeting (antibody, small interfering RNA,
ntisense, and so on) of cytotoxic pathways to inhibit
heir function would have markedly different effects
n subsequent engraftment according to the condi-
ions of the transplantation (Figure 1). It is interesting
o note that the ﬁndings reported to date identifying
ndividual cytotoxic pathways that are not required—
ogether with observations that in some transplanta-
ions, many of these pathways can be simultaneously
nhibited without dampening allograft resistance—
end credence to the notion that identifying the ap-
ropriate effector pathways of resistance could lead to
trategies speciﬁcally blocking these while leaving
any signiﬁcant host immune functions intact early
fter transplantation. Emerging insights into the cel-
ular and molecular mechanisms underlying rejection
f allogeneic HSPCs will facilitate progress toward
he development of more effective nonmyeloablative
onditioning protocols.
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